B3-2

B3-2: sourced facts only. name: "Among them, B3-2 exhibited the strongest antiproliferative activity against FLT3-ITD mutant AML cells, and significantly induced FLT3-ITD protein degradation." [PMID:38820938]; target: "Among them, B3-2 exhibited the strongest antiproliferative activity against FLT3-ITD mutant AML cells, and significantly induced FLT3-ITD protein degradation." [PMID:38820938]; developer: "Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China." [PMID:38820938]; modality: "Here, we report the rational design and evaluation of a series of Gilteritinib-based FLT3-PROTACs." [PMID:38820938]; stage: "More importantly, B3-2 exhibited an oral bioavailability of 5.65%, and oral administration of B3-2 showed good antitumor activity in MV-4-11 xenograft models." [PMID:38820938]